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Objective: To compare Middle East Arabs and Indian subcontinent acute heart failure (AHF) patients.
Methods: AHF patients admitted from February 14, 2012 to November 14, 2012 in 47 hospitals
among 7 Middle East countries.
Results: The Middle Eastern Arab group (4157) was older (60 vs. 54 years), with high prevalence of
coronary artery disease (48% vs. 37%), valvular heart disease (14% vs. 7%), atrial ﬁbrillation (12% vs. 7%),
and khat chewing (21% vs. 1%). Indian subcontinent patients (382) were more likely to be smokers (36%
vs. 21%), alcohol consumers (11% vs. 2%), diabetic (56% vs. 49%) with high prevalence of AHF with
reduced ejection fraction (76% vs. 65%), and with acute coronary syndrome (46% vs. 26%). In-hospital
mortality was 6.5% with no difference, but 3-month and 12-month mortalities were signiﬁcantly high
among Middle East Arabs, (13.7% vs. 7.6%) and (22.8% vs. 17.1%), respectively.
Conclusions: AHF patients from this region are a decade younger than Western patients with high
prevalence of ischemic heart disease, diabetes mellitus, and AHF with reduced ejection fraction.
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E-mail address: prashanthp_69@yahoo.co.in (P. Panduranga).
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There is an urgent need to control risk factors among both groups, as well as the need for setting up
heart failure clinics for better postdischarge management.
# 2015 Cardiological Society of India. Published by Elsevier, a division of Reed Elsevier
India, Pvt. Ltd. All rights reserved.
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Many studies have observed worse prognosis among most
migrant groups or minorities compared to local population
following acute heart failure (AHF) admission.1–3 In addition,
it is noted that people of South Asian (Indian subcontinent)
descent have a high prevalence of comorbidities, which lead
to increased occurrence of heart failure (HF) among these
population.4–7 Furthermore, the etiology and management
of ethnic minority HF patients may vary. Hence, in 2010,
the Canadian Cardiovascular Society published guidelines
on HF in ethnic minority populations in Canada.8 Presently,
there is a signiﬁcant percentage of South Asian population
residing in the Middle East, but little is known about the
etiology, presentation, management, and prognosis for this
population compared to the Middle East population. In a
previous retrospective single-center study from Qatar, it was
observed that HF patients in the Middle East present at
relatively younger age regardless of ethnicity and they
tend to have more comorbidites.9 Gulf CARE (aCute heArt
failuRe rEgistry) is a prospective, multinational, multicenter
registry of patients admitted with the diagnosis of AHF to
47 hospitals in 7 Middle Eastern countries.10 The aim of
this paper is to compare clinical characteristics, manage-
ment, and outcomes between Middle East Arabs and
Indian subcontinent AHF patients enrolled in the Gulf CARE
study.
2. Methods
Gulf CARE registry design, methodology, and hospital
characteristics have been previously described in detail.10
Brieﬂy, patients admitted to the participating hospitals
between February 14, 2012 and November 14th, 2012 were
recruited. Included patients were males and females above 18
year of age with admission diagnosis of AHF. Middle Eastern
Arabs included those from Oman, Yemen, Saudi Arabia,
Kuwait, United Arab Emirates, Qatar, and Bahrain, while
those from the Indian subcontinent included nationals from
India, Pakistan, Afghanistan, Bangladesh, Sri Lanka, and
Nepal. Indian subcontinent ethnicity was determined by self-
report, the gold standard, as well as identifying country of
birth from passport and other national identity documents.
Online data were captured, which included demographic
data, comorbidities, risk factors, precipitating factors, clinical
presentation, investigations, medication history and their
dosages, in-hospital management, and outcome. Follow-up
of patients at 3 months and 1 year was performed. Telephonic
follow-up was done at 3 months and either telephonic or
clinic visit at 1 year. Institutional or national ethical
committee or review board approvals were obtained in eachof the seven participating countries. The study is registered at
clinicaltrials.gov (NCT01467973).
AHF was deﬁned based on ESC criteria.11 AHF was further
classiﬁed as either acute decompensated chronic heart failure
(ADCHF) or new-onset acute heart failure (de novo AHF) based
on ESC guidelines.11 ADCHF was deﬁned as worsening of HF in
patients with a previous diagnosis or hospitalization for HF.
New-onset AHF (de novo AHF) was deﬁned as AHF in patients
with no prior history of HF. Deﬁnitions of data variables in the
CRF were based on the ESC guidelines of 2008 and the ACC
clinical data standards of 2005.11,12 Khat chewing was deﬁned
as chewing khat plant/leaves (Catha edulis containing cath-
ionine, an amphetamine-like stimulant) within 1 month of the
index admission. Idiopathic dilated cardiomyopathy was
deﬁned as a myocardial disorder in which the heart muscle
is structurally and functionally abnormal (in the absence of
coronary artery disease (CAD), hypertension, valvular disease,
or congenital heart disease sufﬁcient to cause the observed
myocardial abnormality). HF with preserved ejection fraction
(HFpEF) was deﬁned as presence of symptoms and/or signs of
HF and a left ventricular ejection fraction (LVEF) >40%.
2.1. Statistical analyses
Descriptive statistics were used to summarize the data. For
categorical variables, frequencies and percentages were
reported and differences between groups were analyzed using
Pearson's chi-square test (or Fisher's exact test for cells <5). For
continuous variables, mean and standard deviation were used
to summarize the data while analysis was done using
Student's t-test. For those variables that were not normally
distributed, median and interquartile ranges (25th and 75th
percentiles) were used to present the data while comparative
analysis was performed using the nonparametric Mann–
Whitney test. An a priori two-tailed level of signiﬁcance was
set at 0.05. Statistical analyses were conducted using STATA
version 13.1 (STATA Corporation, College Station, TX, USA).
3. Results
A total of 47 hospitals in 7 Arabian Gulf states (Bahrain, Kuwait,
Oman, Qatar, Saudi Arabia, United Arab Emirates, and Yemen)
participated in the Gulf CARE project, with a total of 5005
patients enrolled. However, only 4539 met the inclusion
criteria of Gulf citizens and those from the Indian subconti-
nent accounting for almost 92% (n = 4157) and 8% (n = 382),
respectively (Table 1). The overall mean age of the cohort was
59  15 years and 62% (n = 2817) were males. More than half of
the patients (55%, n = 2480) presented with ADCHF while the
rest (45%; n = 2059) had de novo AHF. Cardiologists were the
main healthcare provider for 70% (n = 3199) of the patients.
Comorbid conditions were common, particularly hypertension
Table 1 – Patient characteristics of the Gulf CARE cohort stratified by race.
Characteristic All (n = 4539) Indian subcontinent (n = 382) Gulf citizen (n = 4157) p value
Age, mean (SD) 59  15 54  11 60  15 <0.001
Male gender, n (%) 2817 (62%) 317 (83%) 2500 (60%) <0.001
Main care provider, n (%)
Cardiologist 3199 (70%) 326 (85%) 2873 (69%) <0.001
Internist 1340 (30%) 56 (14%) 1284 (31%)
BMI, kg/m2, median (IQR) 27 (24,31) 26 (24,29) 27 (24,31) <0.001
BMI, kg/m2, n (%)
<18.4 96 (2%) 3 (1%) 93 (2%)
18.4–24.9 1401 (31%) 141 (37%) 1260 (30%) <0.001
25.0–29.9 1703 (38%) 168 (44%) 1535 (37%)
≥30.0 1339 (29%) 70 (18%) 1269 (31%)
Medical history, n (%)
Hypertension 2747 (61%) 217 (57%) 2530 (61%) 0.121
Diabetes mellitus 2236 (49%) 212 (56%) 2024 (49%) 0.011
CAD 2122 (47%) 140 (37%) 1982 (48%) <0.001
Hyperlipidemia 1602 (35%) 120 (31%) 1482 (36%) 0.097
Smokinga 1003 (22%) 139 (36%) 864 (21%) <0.001
Khat 888 (20%) 3 (1%) 885 (21%) <0.001
CKD/dialysis 652 (14%) 58 (15%) 594 (14%) 0.633
Valvular heart disease 602 (13%) 24 (6%) 578 (14%) <0.001
Atrial ﬁbrillation 520 (11%) 27 (7%) 493 (12%) 0.005
Stroke/TIA 371 (8.2%) 16 (4.2%) 355 (8.5%) 0.003
PVD 197 (4.3%) 8 (2.1%) 189 (4.6%) 0.024
Alcoholb 14 (3%) 43 (11%) 101 (2%) <0.001
Clinical presentation, n (%)
Dyspnea 4441 (98%) 363 (95%) 4078 (98%) <0.001
Basal lung crepitations 4157 (92%) 361 (95%) 3796 (91%) 0.032
Orthopnoea 3561 (78%) 283 (74%) 3278 (79%) 0.030
PND 2913 (64%) 196 (51%) 2717 (65%) <0.001
Easy fatigability 2586 (57%) 142 (37%) 2444 (59%) <0.001
Abdominal/lower limb swelling 2031 (45%) 92 (24%) 1939 (47%) <0.001
Chest pain 2037 (45%) 192 (50%) 1845 (44%) 0.027
Gallop 1757 (39%) 143 (37%) 1614 (39%) 0.593
Enlarged tender liver 1290 (28%) 28 (7%) 1262 (30%) <0.001
Type of AHF, n (%)
De novo AHF 2059 (45%) 255 (67%) 1804 (43%) <0.001
ADCHF 2480 (55%) 127 (33%) 2353 (57%)
SD – standard deviation; BMI – body mass index; IQR – interquartile range; CAD – coronary artery disease; PVD – peripheral vascular disease; TIA
– transient ischemic attack; CKD – chronic kidney disease; PND – paroxysmal nocturnal dyspnea; AHF – acute heart failure; ADCHF – acute
decompensated chronic heart failure.
Numbers might not add up to 100% due to rounding off. Analyses were performed using Student's t-test, Mann–Whitney or Pearson's chi-
square test, whenever appropriate.
a Smoking – includes chewing tobacco and/or smoking waterpipe.
b Alcohol – daily.
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n = 2122), and hyperlipidemia (35%; n = 1602). The three most
common presenting signs and symptoms were dyspnea (98%;
n = 4441), basal lung crepitations (92%; n = 4157), and orthop-
noea (78%; n = 3561). On admission, the mean heart rate was
97  23 and the predominant New York Heart Association
(NYHA) class was III/IV (76%; n = 3454). The rest of the
characteristics are shown in Table 1.
Indian subcontinent HF patients were generally associated
with fewer comorbidities compared to Gulf citizens. They were
younger (60 vs. 54 years; p < 0.001), had signiﬁcantly lower
proportion of patients with CAD (37% vs. 48%; p < 0.001), were
khat users (1% vs. 21%; p < 0.001), and had valvular heart
disease (6% vs. 14%; p < 0.001), atrial ﬁbrillation (7% vs. 12%;
p < 0.001), prior stroke/transient ischemic stroke (4.2% vs. 8.5%;
p < 0.001), and peripheral vascular disease (2.1% vs. 4.6%;
p < 0.001). In addition, they were also less likely to present withdyspnea (95% vs. 98%; p < 0.001), orthopnoea (74% vs.79%;
p = 0.030), paroxysmal nocturnal dyspnea (51% vs.65%;
p < 0.001), easy fatigability (37% vs.59%; p < 0.001), abdomi-
nal/lower limb swelling (24% vs. 47%; p < 0.001), and enlarged
tender liver (7% vs. 30%; p < 0.001). However, the Indian
subcontinent patients were more likely to be associated with
diabetes mellitus (56% vs. 49%; p < 0.001), smoking (36% vs.
21%; p < 0.001), and alcohol consumption (11% vs. 2%;
p < 0.001). Furthermore, Indian subcontinent patients were
more likely to present with basal lung crepitations (95% vs.
91%; p = 0.032) and chest pain (50% vs. 44%; p = 0.027).
Table 2 shows the physical, laboratory, ECG, and echocar-
diography ﬁndings. Indian subcontinent patients were
associated with higher baseline heart rate (102 vs. 96 beats/
min; p < 0.001), systolic BP (144 vs.137 mmHg; p < 0.001),
diastolic BP (87 vs.81 mmHg; p < 0.001), and lower admission
serum urea (9 vs. 12 mmol/L; p < 0.001) and serum potassium
Table 2 – Physical, laboratory, ECG, and echocardiography investigations by race.
Characteristic All (n = 4539) Indian subcontinent (n = 382) Gulf citizen (n = 4157) p value
Physical, mean (SD), unless speciﬁed otherwise
HR, beats/min (n = 4386) 97  23 102  24 96  23 <0.001
SBP, mmHg (n = 4388) 137  34 144  39 137  34 <0.001
DBP, mmHg (n = 4388) 81  20 87  23 81  19 <0.001
Raised JVP > 6 cm, n (%) 2251 (50%) 172 (45%) 2079 (50%) 0.062
Laboratory investigations, mean (SD), unless speciﬁed otherwise
First serum creatinine, mmol/L 130  117 128  102 130  118 0.732
First serum urea, mmol/L 12  8 9  6 12  9 <0.001
First serum potassium, mmol/L 4.2 (3.9–4.6) 4.1 (3.7–4.5) 4.2 (3.9–4.6) 0.002
BNP, pg/mL, median, (n = 334) 1300 (890–5209) 2396 (1503–5000) 1293 (890–5223) 0.370
NT-pro BNP, pg/mL, (n = 669) 3059 (1260–6986) 4023 (1797–7590) 2778 (1138–6891) 0.021
e-GFR, mL/min, (n = 4476) 64 (44–87) 70 (49–88) 63 (44–87) 0.029
Hemoglobin, g/dL 12.6 (11–14) 13.6 (12–15) 12.5 (11–14) <0.001
Total cholesterol, mmol/L, (n = 3268) 4.6 (3.6–5.6) 4.4 (3.5–5.3) 4.6 (3.6–5.6) 0.155
HbA1c, % (n = 1792) 6.7 (5.5–8.5) 7.4 (6.0–9.8) 6.7 (5.5–8.5) <0.001
ECG, n (%), unless speciﬁed otherwise
Rhythm statusa
Sinus rhythm 3740 (82%) 328 (86%) 3412 (82%) 0.162
AF/ﬂutter 589 (13%) 42 (11%) 547 (13%)
CHB 59 (1.3%) 4 (1.1%) 55 (1.3%)
Paced 68 (1.5%) 1 (0.3%) 67 (1.6%)
SVT 24 (0.5%) 3 (0.8%) 21 (0.5%)
Others 59 (1.3%) 4 (1.1%) 55 (1.3%)
LV hypertrophy 1350 (30%) 116 (30%) 1234 (30%) 0.780
ST-depression/T-inversion 1987 (44%) 226 (59%) 1761 (42%) <0.001
STEMI 474 (10%) 101 (26%) 373 (9%) <0.001
Pathological Q waves 1061 (23%) 104 (27%) 957 (23%) 0.063
QRS duration = > 0.12 ms
No 3616 (80%) 317 (83%) 3299 (79%) 0.006
LBBB 595 (13%) 34 (9%) 561 (14%)
RBBB 191 (4.2%) 24 (6.3%) 167 (4.0%)
IVCD 137 (3.0%) 7 (1.8%) 130 (3.1%)
Echocardiography, n (%), unless speciﬁed otherwise
LVEF, %, med (IQR) (n = 4150) 35 (25–45) 35 (25–40) 35 (25–45) <0.001
LVEF > 40% (n = 4150) 1416 (34%) 85 (24%) 1331 (35%) <0.001
SD – standard deviation; ECG – electrocardiography; HR – heart rate; SBP – systolic blood pressure; DBP – diastolic blood pressure; JVP – jugular
venous pressure; BNP – B-type natriuretic peptide; NT-pro BNP – N-terminal B-type natriuretic peptide; GFR – glomerular ﬁltration rate; AF –
atrial ﬁbrillation; CHB – complete heart block; SVT – supraventricular tachycardia; LV – left ventricular; STEMI – ST-segment elevation
myocardial infarction; LBBB – left bundle branch block; RBBB – right bundle branch block; IVCD – intraventricular conduction delay; LVEF – left
ventricular ejection fraction.
Analyses were performed using Student's t-test or Mann–Whitney or Pearson's chi-square or Fisher's exact tests, whenever appropriate.
a Percents may not add up to 100% due to rounding off.
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were associated with lower, NT-pro BNP (2788 vs. 4023 pg/mL;
p = 0.021), e-GFR (63 vs. 70 mL/min; p = 0.029), hemoglobin
(12.5 vs. 13.6 g/dL; p < 0.001), and HbA1c (6.7 vs. 7.4 g/dL;
p < 0.001), as well as lower proportion of patients with ST-
depression/T-inversion (42% vs. 59%; p < 0.001) and STEMI (9%
vs. 26%; p < 0.001). Furthermore, the proportion of patients
with LVEF >40% was signiﬁcantly lower in Indian subconti-
nent patients when compared to Gulf citizens (24% vs. 35%;
p < 0.001).
Eighty-two percent (n = 3740) of the patients were in sinus
rhythm with 13% demonstrating atrial ﬁbrillation or ﬂutter.
Overall 80% (n = 3616) of patients had QRS duration <120 ms
with only 13% (n = 595) of the cohort presenting with left
bundle branch block (LBBB) morphology on ECG. Indian
subcontinent patients were less likely to have LBBB than Gulf
citizens (9% vs.14%; p = 0.006).Table 3 presents cardiac procedures, in-hospital course,
precipitating factors, etiology, and in-hospital outcomes. A
total of 5.8% and 1.4% of the patients had PCI and CABG,
respectively, with Indian subcontinent patients more likely to
have these procedures than Gulf citizens (16% vs. 5%, PCI;
p < 0.001) (3.1% vs. 1.3%, CABG; p = 0.003). The three most
prevalent in-hospital events/courses included infection re-
quiring therapy (24%), requirement of inotropes (16%) and
noninvasive ventilation (NIV) (9%). Indian subcontinent
patients were more likely to have NIV (16% vs. 9%;
p < 0.001), cardiogenic shock (11% vs. 8%; p = 0.039), ventricular
tachycardia/ﬁbrillation requiring therapy (7.1% vs. 4.3%;
p = 0.014), and be on intra-aortic balloon pump (IABP) (4.7%
vs. 1.4%; p < 0.001).
The three most common precipitating causes of HF were
acute coronary syndrome (ACS) (27%), noncompliance with
medications (20%), and infection (15%). Indian subcontinent
Table 3 – Cardiac procedures, in-hospital course, precipitating causes, and etiology of heart failure, NYHA classification,
and in-hospital outcome stratified by race.
Characteristic All (n = 4539) Indian subcontinent (n = 382) Gulf citizen (n = 4157) p value
Cardiac procedures, during admission, n (%)
PCI 265 (5.8%) 63 (16%) 202 (5%) <0.001
CABG 65 (1.4%) 12 (3.1%) 53 (1.3%) 0.003
Device therapy 111 (2.5%) 11 (2.9%) 100 (2.4%) 0.337
CRT-D 24 2 22
CRT-P 1 0 1
ICD 44 7 37
PPM 42 2 40
Valve repair/replacement 83 (1.8%) 1 (0.3%) 82 (2.0%) 0.009
In-hospital course, n (%)
Infection requiring therapy 1100 (24%) 96 (25%) 1004 (24%) 0.669
Inotropes 728 (16%) 55 (14%) 673 (16%) 0.361
NIV 416 (9%) 62 (16%) 354 (9%) <0.001
Intubation/ventilation 387 (8.5%) 37 (9.7%) 350 (8.4%) 0.396
Cardiogenic shock 373 (8%) 42 (11%) 331 (8%) 0.039
AFib requiring therapy 275 (6.1%) 18 (4.7%) 257 (6.2%) 0.249
Blood transfusion 231 (5.1%) 18 (4.7%) 213 (5.1%) 0.726
VT/VF requiring therapy 207 (4.6%) 27 (7.1%) 180 (4.3%) 0.014
Acute dialysis/ultraﬁltration 122 (2.7%) 7 (1.8%) 115 (2.8%) 0.280
IABP 75 (1.7%) 18 (4.7%) 57 (1.4%) <0.001
Stroke 65 (1.4%) 4 (1.1%) 61 (1.5%) 0.655
Precipitating causes of heart failure, n (%)
Acute coronary syndrome 1235 (27%) 175 (46%) 1060 (26%) <0.001
Noncompliance with meds 905 (20%) 52 (14%) 853 (21%)
Infection 679 (15%) 33 (9%) 646 (16%)
Uncontrolled hypertension 370 (8.2%) 44 (12%) 326 (7.8%)
Uncontrolled arrhythmias 257 (5.9%) 13 (3.4%) 254 (6.1%)
Worsening renal failure 181 (4.0%) 13 (3.4%) 168 (4.0%)
Anemia 138 (3.0%) 6 (1.6%) 132 (3.2%)
Etiology of heart failurea, n (%)
Ischemic HD 2433 (54%) 250 (65%) 2183 (53%) <0.001
Idiopathic cardiomyopathy 806 (18%) 53 (14%) 753 (18%)
Hypertensive HD 741 (16%) 48 (13%) 693 (17%)
Valvular HD 407 (9.0%) 19 (5.0%) 388 (9.3%)
Pulmonary hypertension 120 (2.6%) 6 (1.6%) 114 (2.7%)
Congenital HD 17 (0.4%) 3 (0.8%) 14 (0.3%)
Myocarditis 14 (0.3%) 3 (0.8%) 11 (0.3%)
NYHA classiﬁcationb at discharge, n (%) [n = 4542]
I 2229 (54%) 154 (44%) 2075 (55%) <0.001
II 1554 (38%) 179 (51%) 1375 (37%)
III 107 (2.6%) 13 (3.7%) 94 (2.5%)
IV 216 (5.3%) 4 (1.1%) 212 (5.6%)
Outcome, n (%)
Died 296 (6.5%) 17 (4.5%) 279 (6.7%) 0.087
NYHA – New York Heart Association; PCI – percutaneous coronary intervention; CABG – coronary artery bypass graft; CRT-D – cardiac
resynchronization therapy with deﬁbrillation; CRT-P – cardiac resynchronization therapy with pacemaker; ICD – implantable cardioverter-
deﬁbrillator; PPM – permanent pacemaker; NIV – noninvasive ventilation; AFib – atrial ﬁbrillation; VT/VF – ventricular tachycardia/ventricular
ﬁbrillation; IABP – intra-aortic balloon pump; Meds – medications; HD – heart disease.
a One patient had a missing etiology of heart failure.
b For NYHA classiﬁcation, analytics excluded those that died (n = 296; 6.5%) as well as those that left against medical advice (n = 137; 3.0%)
(LAMA) (n = 433 = 4539  4106). Analyses were performed using Pearson's chi-square or Fisher's exact tests, whenever appropriate.
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26%; p < 0.001) and uncontrolled hypertension (12% vs. 7.8%;
p < 0.001) while Gulf citizens were more likely to be associated
with noncompliance with medications (21% vs. 14%; p < 0.001)
and infection (16% vs. 9%; p < 0.001) as precipitating causes of
HF. The three most prevalent etiologies of HF were CAD (54%),
idiopathic cardiomyopathy (18%), and hypertensive heart
disease (HHD) (16%). Valvular heart disease, as an etiology,
accounted for 9% (n = 407) of the patients.Table 4 outlines discharge medications of the Gulf CARE
cohort. Among the discharged medications, and besides
aspirin (81%) and statins (72%), the most prescribed medica-
tions were diuretics (94%), angiotensin-converting enzyme
inhibitors/angiotensin II receptor blockers (ACEIs/ARB) (79%),
beta-blockers (71%), and aldosterone antagonists (44%). Indian
subcontinent patients were more likely to be prescribed
aspirin (86% vs. 81%; p = 0.015), clopidogrel (57% vs. 36%;
p < 0.001), and statin (83% vs. 71%; p < 0.001) while Gulf citizens
Table 4 – Discharge medications of the Gulf CARE cohort stratified by race.
Medications at dischargea All (n = 4106) Indian subcontinent (n = 350) Gulf citizen (n = 3756) p value
Diuretics 3862 (94%) 322 (92%) 3540 (94%) 0.089
Aldosterone antagonist 1800 (44%) 121 (35%) 1679 (45%) <0.001
ACEI 2510 (61%) 215 (61%) 2295 (61%) 0.905
ARB 723 (18%) 39 (11%) 684 (18%) 0.001
Beta-blocker 2925 (71%) 251 (72%) 2674 (71%) 0.837
Digoxin 1045 (25%) 86 (25%) 959 (26%) 0.693
Nitrates 1583 (39%) 136 (39%) 1447 (39%) 0.903
Hydralazine 292 (7.1%) 30 (8.6%) 262 (7.0%) 0.267
Aspirin 3344 (81%) 302 (86%) 3042 (81%) 0.015
Clopidogrel 1538 (37%) 200 (57%) 1338 (36%) <0.001
Statin 2955 (72%) 290 (83%) 2665 (71%) <0.001
CCB 623 (15%) 53 (15%) 570 (15%) 0.987
Anticoagulant 751 (18%) 51 (15%) 700 (19%) 0.060
Anti-arrhythmic 195 (4.8%) 15 (4.3%) 180 (4.8%) 0.670
Ivabradine 201 (4.9%) 19 (5.4%) 182 (4.9%) 0.629
ACEI – angiotensin converting enzyme inhibitor; ARB – angiotensin receptor blocker; CCB – calcium channel blocker.
a Medications at discharge excluded those that died (n = 296; 6.5%) as well as those that left against medical advice (n = 137; 3.0%) (LAMA)
(n = 433 = 4539  4106). Analyses were performed using Pearson's chi-square.
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) s 3 6 – s 4 4 S41were likely to be prescribed aldosterone antagonist (45% vs.
35%; p < 0.001) and ARB (18% vs. 11%; p < 0.001).
Table 5 shows follow-up data at 3 and 12 months. Follow-up
status was complete in 98.5% of patients at 3 and 12 months. At
3-month follow-up, Indian subcontinent patients were less
likely to be hospitalized for HF (15.1% vs. 20.5%; p < 0.001). They
were more likely to undergo CABG (7.4% vs. 3.3%; p < 0.001) but
less likely to have device therapy (0.4% vs. 1.1%; p = 0.024) when
compared to Gulf citizens. Importantly, Indian subcontinentTable 5 – Gulf CARE follow-up, 3- and 12-month outcomes by 
Outcome All (n = 4539) Indian subco
3-month outcomes
Losses to follow-up, n (%) 65 (1.4%) 5 (1
Hospitalization for HF 903 (18.0%) 414
LOS, median (IQR), days 6 (4–10) 6 (4
CABG 258 (5.2%) 169
Device therapy 40 (0.8%) 9 (0
CRT-D 10 1 
ICD 20 5 
PPM 10 3 
Died 597 (13.2%) 29 
12-month outcomes
Losses to follow-up, n (%) 76 (1.5%) 39 
Hospitalization for HF 1075 (21.5%) 427
LOS, median (IQR), days 6 (3–10) 5 (3
CABG 380 (7.6%) 209
Device therapy 82 (1.6%) 42 
CRT-D 13 72 
ICD 34 13 
PPM 34 27 
CRT-P 1 0 
Died 1012 (20.2%) 390
HF – heart failure; LOS – length of hospital stay; IQR – interquartile range;
implantable cardioverter-deﬁbrillator; PPM – permanent pacemaker; CR
coronary artery bypass graft.
Mortality was cumulative also including those that died in hospital. Ana
test, whenever appropriate.patients were less likely to die compared to Gulf citizens (7.6%
vs. 13.7%; p = 0.003). Over the 12-month follow-up period,
Indian subcontinent patients were associated with lower
hospitalization rate for HF (18.8% vs. 23.7%; p < 0.001) but
higher use of device therapy (1.9% vs. 1.5%; p < 0.001) and the
procedure, CABG (9.2% vs. 6.3%; p < 0.001) when compared
with Gulf citizens. Furthermore, Indian subcontinent patients
were associated with lower all-cause mortality when com-
pared to Gulf citizens (17.1% vs. 22.8%; p < 0.001).race (n = 5005).
ntinent (n = 382) Gulf citizen (n = 4157) p value
.3%) 60 (1.4%) 0.832
 (15.1%) 489 (20.5%) <0.001
–9) 6 (4–10) 0.942
 (7.4%) 89 (3.3%) <0.001
.4%) 31 (1.1%) 0.024
9
15
7
(7.6%) 568 (13.7%) 0.003
(1.7%) 37 (1.4%) 0.303
 (18.8%) 648 (23.7%) <0.001
–8) 6 (4–11) <0.001
 (9.2%) 171 (6.3%) <0.001
(1.9%) 40 (1.5%) <0.001
11
21
7
1
 (17.1%) 622 (22.8%) <0.001
 CRT-D – cardiac resynchronization therapy with deﬁbrillation; ICD –
T-P – cardiac resynchronization therapy with pacemaker; CABG –
lyses were performed using Mann–Whitney or Pearson's chi-square
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) s 3 6 – s 4 4S424. Discussion
The present study is the ﬁrst multinational multicenter
prospective study to compare clinical characteristics and
long-term prognosis of AHF patients from Middle East Arab
population and Indian subcontinent, residing in the Middle
East. The results of this study demonstrate that AHF patients
from this region are a decade younger than Western patients
with high prevalence of ischemic heart disease and diabetes,
and a higher preponderance to AHF with reduced ejection
fraction. Middle East Arabs were associated with higher
rates of HF risk factors. In-hospital mortality was similar,
but 3-month and 12-month mortalities were high in the Middle
East group.
Even though, the Middle Eastern Arab patients were older
compared to Indian subcontinent patients (60 vs. 54 years),
both were a decade younger than the Western population (70
years).13,14 In the African AHF registry, mean age was 52
years.15 This onset of AHF at early age in both Middle East and
Indian subcontinent patients may be due to overall younger
population in the region, as well as higher prevalence of
cardiac risk factors at a younger age that was noted in previous
HF registries from Qatar and Saudi Arabia.8,16 Another factor
for younger age of Indian subcontinent patients could be due
to presence of a younger expatriate workforce residing in the
Middle East, speciﬁcally blue-collar workers.
When compared to the Western population, it is well
known that South Asian HF patients are having lower body
mass index, past CAD, or myocardial infarction, and were
more often diabetic, and were less often smokers and alcohol
consumers.4–7,17,18 However, in this study, Indian subconti-
nent patients were more likely to be smokers, alcohol
consumers, and less obese with high prevalence of diabetes
mellitus compared to Middle East patients. Smoking and
alcohol consumption is high among Indian subcontinent
patients possibly due to presence of young workers deprived of
family presence in their country of work. Diabetes mellitus
was high among those from the Indian subcontinent and
Middle East cohorts at 56% and 49%, respectively. The burden
of diabetes mellitus in the Middle East countries is highest
among all nations (23 vs. 8% global prevalence) As per
International Diabetic Federation statistics,19 diabetic patients
are increasingly prone for HF with many factors contributing
to HF, such as severe diffuse multivessel CAD, recurrent
myocardial infarction, and diabetic cardiomyopathy with both
systolic and diastolic dysfunction.20
In this study, hypertension was the commonest risk factor
in both cohorts, but Middle East patients had increasingly
higher prevalence of CAD, obesity, valvular heart disease,
atrial ﬁbrillation, and khat chewing. This indicates that Middle
East HF patients are at higher risk for HF than the Indian
subcontinent patients. In a recent population-based study,
among individuals without cardiovascular disease, higher BMI
was found to have an independent, linear association with
subclinical myocardial injury, as assessed by hs-cTnT levels
and provided complementary prognostic information regard-
ing the risk of incident HF.21 It is presumed that Indian
subcontinent patients generally have high prevalence of
valvular heart disease due to high incidence of rheumaticfever in that region, but this study shows that signiﬁcant
number of Middle East valvular heart disease patients
present with AHF even though the etiology data of valvular
heart disease was not collected. In a systemic review of
global burden of AF, it was observed that AF occurrence is
related to increasing age, presence of valvular heart disease,
and ethnicity.22 Added to this, there is high prevalence of
khat chewing, which is an amphetamine-like stimulant,
which can cause euphoria, hypertension, myocardial infarc-
tion, and dilated cardiomyopathy. In a Gulf acute coronary
syndrome registry analysis, khat chewing was an indepen-
dent risk factor for in-hospital mortality, recurrent ischemia,
and HF.23 All these indicate that countries in this region are
undergoing fast epidemiological transition and are facing the
double burden of traditional cardiac risk factors, as well as
nontraditional risk factors for HF in this region like khat
chewing.
In the Indian subcontinent patients, ischemic heart disease
as etiology and ACS as precipitating factor were more
common, as well as STEMI-precipitating AHF. As noted in
this registry, ischemic etiology is the commonest etiology of
HF in the American and European registries, except in the
African registry.13–15 In this study, Indian subcontinent
patients when compared to Middle East HF patients had more
occurrence of ACS, speciﬁcally ST-elevation MI.24 Large studies
have documented higher incidence of ST-elevation MI among
South Asians.24,25 Also, younger age patients are known to
present more frequently with ST-elevation MI.26–28 This may
be the main reason for Indian subcontinent patients present-
ing more with de novo AHF.
Another important ﬁnding from this registry is that
Indian subcontinent patients presented more with AHF with
reduced ejection fraction (76%) compared to Middle East
patients (65%), which is similar to European registry, but
more that the American registry.13,14 In both cohorts, this
high prevalence of left ventricular systolic dysfunction may
be due to high prevalence of ischemic heart disease, ACS,
especially STEMI, as well as underlying diabetic cardiomy-
opathy or khat chewing (in Middle East patients). In this
study, NT-pro-BNP level was found to be signiﬁcantly higher
in Indian subcontinent patients when compared to Middle
East patients. This ﬁnding has been noted before in a study
where Asian and black patients with HF had higher BNP
levels at admission compared with white and Hispanic
patients.29 BNP levels at admission provided prognostic
value for in-hospital mortality and hospital LOS irrespective
of race/ethnicity.29
With regard to treatment there were no signiﬁcant
differences in discharge medications, except for aldosterone
antagonists, which were used more in Middle East patients,
and antiplatelet/statin therapy, which were used more in
Indian subcontinent patients. Although, Indian subcontinent
patients had more HFrEF, aldosterone use was suboptimal.
However, even though overall cardiac procedures were less in
the entire registry, Indian subcontinent patients received more
PCI or CABG. This may be due to higher occurrence of ACS/
STEMI in these patients, as well as because they were younger.
It has been noted in few studies, as well as in the Indian
CREATE ACS registry, that younger patients with STEMI
receive more frequently evidence-based therapies compared
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) s 3 6 – s 4 4 S43with patients with unstable angina and non-ST-elevation MI.28
Noncompliance to medications was noted more with Middle
East patients, which may be due to racial disparities in health
literacy, as noted in a study.30
In-hospital mortality was 6.5% in both cohorts with no
difference, but 3-month and 12-month hospitalization and
mortality was signiﬁcantly high among Middle East Arabs
when compared to Indian subcontinent patients. These
disparities may be attributable to poorer outpatient manage-
ment following discharge, as there was high prevalence of
precipitating factors, noncompliance to medications, and
underutilization of cardiac procedures and lack of specialist
HF clinics in the region. The Indian subcontinent patients, as
noted in this study, have cardiologist as main care provider
and may have followed-up with cardiologist in private clinics
resulting in better care, and a few of them ﬂy to their own
country for procedures and come back. This underscores need
for aggressive outpatient management of HF patients post-
discharge from hospital and setting up of specialist HF clinics
in the region for Middle East patients.
4.1. Limitations
There are several limitations in this study. As with any registry
study, confounding or unknown variables could have inﬂu-
enced the results. The Indian subcontinent patients were
those working and residing in the Middle East, and thus the
results are not necessarily generalizable to the entire South
Asian countries. Indian subcontinent patients were predomi-
nantly men who were compared with Middle East Arab men
and women. Majority of the Indian subcontinent patients are
‘‘blue collar’’ workers who may not self-report some of risk
factors, which may have led to inaccuracies in reporting.
Echocardiographic interpretation was at the discretion of the
echo cardiographer performing the study; no centralized
evaluation was done. Reasons for underusage of procedures
were not known in this study.
5. Conclusions
AHF patients from this region are a decade younger than
Western patients with high prevalence of ischemic heart
disease, diabetes mellitus, and a higher preponderance to AHF
with reduced ejection fraction. Middle East Arabs were
associated with higher rates of HF risk factors. In-hospital
mortality was similar, but 3-month and 12-month mortalities
were high in the Middle East group. There is an urgent need to
prevent/control ischemic heart disease and diabetes to reduce
HF burden among those in both groups, as well as the need for
setting up HF clinics for better postdischarge management of
HF patients.
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